+30 years of global experience across multiple conditions1-4
CHRONIC MIGRAINE*
A debilitating disease affecting 1.4-2.2% of adults globally.5,6 Explore chronic migraine from the patient's perspective, and learn about how BOTOX® could positively impact your patients' lives7,8
POST-STROKE SPASTICITY‡
Spasticity is a common consequence of neurological disorders such as stroke and can have a substantial effect on a patient's ability to undertake basic everyday tasks.11 Learn about the importance of early identification12 and the potential benefits BOTOX® could offer10
BOTOX® has an efficacy and tolerability profile from
+30 years of global use in a range of conditions2-4
Explore the licensed indications timeline1
First approved by the US FDA in 198913 and 25 years of experience in the UK1
UK approval:
blepharospasm and hemifacial spasm1
UK approval:
idiopathic cervical dystonia1
UK approval:
juvenile cerebral palsy1
UK approval:
axillary hyperhidrosis1
UK approval:
post-stroke wrist and hand spasticity1
UK approval:
chronic migraine1
UK approval:
neurogenic detrusor overactivity1
UK approval:
overactive bladder1
UK approval:
post-stroke ankle spasticity1
UK approval:
post-stroke ankle and foot spasticity1
UK approval:
ankle and foot spasticity in paediatric cerebral palsy1
*BOTOX® is indicated for prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).10
†BOTOX® is indicated for the management of bladder dysfunctions in adult patients who are not adequately managed with anticholinergics: overactive bladder with symptoms of urinary incontinence, urgency and frequency; neurogenic detrusor overactivity with urinary incontinence due to subcervical spinal cord injury (traumatic or non-traumatic), or multiple sclerosis.10
‡BOTOX® is indicated for the symptomatic treatment of: elbow, wrist and hand in paediatric cerebral palsy patients and ankle and foot in ambulant paediatric cerebral palsy patients, two years of age or older as an adjunct to rehabilitative therapy; wrist and hand disability due to upper limb spasticity and ankle, foot disability due to lower limb spasticity, associated with stroke in adults.10
References
- Allergan Ltd. Data on file 014
- Allergan. Data on file. INT/0423/2016
- Aurora S K, Winner P et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51(9):1358-1373
- Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. J Headache Pain 2018;19(1):13
- Natoli J L, Manack A et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010;30(5):599-609
- Steiner T J, Stovner L J et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 2018;19(1):17
- Dodick D W, Turkel C C et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50(6):921-936
- Khalil M, Zafar H W et al. Prospective analysis of the use of onabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain 2014;15:54
- Stewart W F, Van Rooyen J B et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-336
- BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk. Accessed October 2022
- Royal College of Physicians. Spasticity in adults: management using botulinum toxin. National guidelines, 20 March 2018. Available at: www.rcplondon.ac.uk. Accessed October 2022
- Glaess-Leistner S, Ri S J et al. Early clinical predictors of post-stroke spasticity. Top Stroke Rehabil 2020:1-11
- Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) 2012;4(10):913-939
Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on [email protected]
Date of preparation: October 2022. UK-BTX-220199.
